Mountain Pacific Investment Advisers Inc. ID Has $33.78 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Mountain Pacific Investment Advisers Inc. ID raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 142,904 shares of the medical research company’s stock after purchasing an additional 9,723 shares during the quarter. Charles River Laboratories International makes up about 2.1% of Mountain Pacific Investment Advisers Inc. ID’s portfolio, making the stock its 19th biggest holding. Mountain Pacific Investment Advisers Inc. ID owned 0.28% of Charles River Laboratories International worth $33,783,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in CRL. abrdn plc lifted its stake in Charles River Laboratories International by 872.0% in the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after purchasing an additional 109,275 shares during the last quarter. Regency Capital Management Inc. DE bought a new stake in Charles River Laboratories International in the 4th quarter valued at $3,703,000. WCM Investment Management LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $1,396,000. DekaBank Deutsche Girozentrale lifted its holdings in Charles River Laboratories International by 98.6% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock valued at $3,333,000 after purchasing an additional 6,997 shares during the last quarter. Finally, AMG National Trust Bank bought a new position in Charles River Laboratories International during the third quarter worth $1,119,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, VP William D. Barbo sold 4,050 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock valued at $3,693,663 in the last 90 days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 0.5 %

Shares of NYSE CRL opened at $229.03 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The stock has a market cap of $11.80 billion, a P/E ratio of 24.87, a price-to-earnings-growth ratio of 1.88 and a beta of 1.40. The firm has a 50-day moving average of $253.48 and a 200 day moving average of $222.64. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.98 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. UBS Group raised their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Citigroup raised their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Argus boosted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, Guggenheim lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).